Medtech teams are often asked to prove value quickly. The natural response is to reduce the product to its most visible screen and defer everything that looks like infrastructure, traceability, or quality work.

That creates a demo, not necessarily a useful minimum product. If the first release cannot explain where a value came from, who changed it, or what the user should do when the workflow fails, the team has saved time only to spend it again later.

An MVP can be small, but it cannot be vague about its intended use. The team needs to decide which users, decisions, devices, data states, and workflow paths are genuinely in scope.

That boundary also defines what the product must refuse to do. A clear limitation is safer and easier to test than a broad promise supported by incomplete records.

The work begins with a narrow workflow and its risks. Core identities, permissions, timestamps, version information, audit events, and explicit error states are preserved from the first release.

Design focuses on making the intended path understandable while engineering protects the underlying record. Together they create a product that can be evaluated honestly rather than judged only by how quickly a user reaches the next screen.

Features that do not support the chosen use case are postponed. Evidence-producing functions that explain the use case are not treated as optional polish.

This usually means fewer workflows, but stronger behavior inside each one: clear handoffs, recoverable errors, visible status, and a record of what happened.

The evidence includes intended-use boundaries, risk assumptions, workflow definitions, event logs, test cases, usability observations, and a plan for expanding scope. It should also show which assumptions remain open.

A thin medtech product is credible when its boundaries are visible and its essential records remain reliable. Speed comes from choosing less, not from removing the information needed to understand what the product did.